Abstract
Simple SummaryTumour cells in colorectal cancer liver metastases (CRCLM) obtain their blood supply via two major mechanisms: (i) sprouting angiogenesis, through the generation of new vessels; (ii) vessel co-option, where the cancer cells hijack the pre-existing vasculature. The current treatment for CRCLM targets angiogenesis; however, these treatments are ineffective on cancer cells utilizing vessel co-option to gain their blood supply. Our study suggests that cancer cells stimulate phenotypic alterations in the cells of surrounding liver tissue (hepatocytes) in vessel co-opting lesions. These modifications facilitate cancer cells to infiltrate through the liver tissue and hijack the pre-existing vasculature to obtain oxygen and nutrients.Vessel co-option is correlated with resistance against anti-angiogenic therapy in colorectal cancer liver metastases (CRCLM). Vessel co-opting lesions are characterized by highly motile cancer cells that move toward and along the pre-existing vessels in the surrounding nonmalignant tissue and co-opt them to gain access to nutrients. To access the sinusoidal vessels, the cancer cells in vessel co-opting lesions must displace the hepatocytes and occupy their space. However, the mechanisms underlying this displacement are unknown. Herein, we examined the involvement of apoptosis, autophagy, motility, and epithelial–mesenchymal transition (EMT) pathways in hepatocyte displacement by cancer cells. We demonstrate that cancer cells induce the expression of the proteins that are associated with the upregulation of apoptosis, motility, and EMT in adjacent hepatocytes in vitro and in vivo. Accordingly, we observe the upregulation of cleaved caspase-3, cleaved poly (ADP-ribose) polymerase-1 (PARP-1) and actin-related protein 2/3 (ARP2/3) in adjacent hepatocytes to cancer cell nests, while we notice a downregulation of E-cadherin. Importantly, the knockdown of runt-related transcription factor 1 (RUNX1) in cancer cells attenuates the function of cancer cells in hepatocytes alterations in vitro and in vivo. Altogether, our data suggest that cancer cells exploit various mechanisms to displace hepatocytes and access the sinusoidal vessels to establish vessel co-option.
Highlights
Introduction conditions of the Creative CommonsColorectal cancer (CRC) is the third most common diagnosed cancer and the second leading cause of cancer death worldwide [1]
We explored the contribution of apoptosis, autophagy, epithelial–mesenchymal transition (EMT), and motility in hepatocyte displacement by cancer cells in vessel co-opting colorectal cancer liver metastases (CRCLM)
Hepatocyte replacement by cancer cells was frequently observed at the edge of cancer cell nests in vessel co-opting replacement histopathological growth pattern (RHGP) lesions, which allowed the cancer cells to take over the hepatocyte-occupied space to hijack the sinusoids and obtain a blood supply [8,10,13]
Summary
Colorectal cancer (CRC) is the third most common diagnosed cancer and the second leading cause of cancer death worldwide [1]. Metastases account for most of the CRCrelated death [2,3]. 30–40% of the patients are found to develop metachronous metastases and another 25–30% of the patients develop liver metastases during the follow-up [4]. Surgical resection is the main treatment approach for CRCLM patients, which can achieve 5-year survival rates above 50%. Only 20% of the patients are qualified for upfront surgery and the rest are left with palliative options [5,6]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.